By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury ...

European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

DHAKA, BANGLADESH - Media OutReach Newswire - 10 January 2025 - The Best Places to Work certification program has recognized Foodpanda and Novo Nordisk as the top two best places to work in ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.

The collaboration now encompasses additional drug programmes. Credit: aslysun/Shutterstock. Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, ...

The randomised, double-blind, placebo-controlled trial sought five cohorts of 120 obese patients who are not type-2 diabetic. Credit: shutterstock / Alones New York obesity healthcare firm, Metsera, ...